According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “
Separately, Ladenburg Thalmann started coverage on shares of BioTime in a research report on Friday, September 23rd. They set a buy rating and a $6.00 price target on the stock.
Shares of BioTime (NYSEMKT:BTX) opened at 3.55 on Monday. The stock’s 50 day moving average is $3.47 and its 200 day moving average is $3.04. BioTime has a 12 month low of $2.02 and a 12 month high of $4.51. The stock’s market capitalization is $360.92 million.
BioTime (NYSEMKT:BTX) last released its quarterly earnings data on Tuesday, August 9th. The company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.43. The business earned $1.27 million during the quarter, compared to analyst estimates of $1.75 million. Analysts anticipate that BioTime will post ($0.22) earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Broadwood Capital Inc. raised its stake in shares of BioTime by 12.3% in the second quarter. Broadwood Capital Inc. now owns 24,897,032 shares of the company’s stock valued at $64,981,000 after buying an additional 2,732,636 shares during the period. KCG Holdings Inc. bought a new stake in shares of BioTime during the second quarter valued at about $133,000. State Street Corp increased its position in BioTime by 12.6% in the second quarter. State Street Corp now owns 886,312 shares of the company’s stock valued at $2,312,000 after buying an additional 98,889 shares in the last quarter. Rhumbline Advisers increased its position in BioTime by 12.3% in the second quarter. Rhumbline Advisers now owns 48,181 shares of the company’s stock valued at $126,000 after buying an additional 5,270 shares in the last quarter. Finally, Teachers Advisors Inc. increased its position in BioTime by 15.1% in the second quarter. Teachers Advisors Inc. now owns 92,984 shares of the company’s stock valued at $243,000 after buying an additional 12,213 shares in the last quarter.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.